North America Musculoskeletal Disorders Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Parenteral and Oral), By Drug Type (Analgesics, DMARDs, Corticosteroids), By Country and Growth Foreca

North America Musculoskeletal Disorders Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration (Parenteral and Oral), By Drug Type (Analgesics, DMARDs, Corticosteroids), By Country and Growth Forecast, 2023 - 2029

The North America Musculoskeletal Disorders Drugs Market would witness market growth of 3.0% CAGR during the forecast period (2023-2029).

Musculoskeletal disorders (MSDs) are injuries and conditions that affect the human body's musculoskeletal system, which consists of bones, discs, tendons, ligaments, muscles, nerves, and blood vessels, and are also responsible for the body's movement. MSDs can affect numerous body regions, including the neck, upper and lower back, shoulders, and extremities, including the arms, legs, hands, and feet.

Manifestations of these disorders include pain, weakness, rigidity, swelling, and restricted range of motion. In addition, musculoskeletal disorders are characterized by swelling, stiff joints, dull pains, and recurrent pain. Medications include corticosteroids, analgesics, and disease-modifying anti-rheumatic medicines (DMARDs). These medications treat inflammation, pain, and other symptoms related to these conditions in various ways.

Over 4.2 million Canadians (16%) aged 15 or older reported having arthritis in 2007-08. By 2031, this figure will rise to almost 7 million (20%) due to the aging population. Although arthritis is more common in older people, it affects people of all ages, including those who are in the prime of their life. Although there is no known cure for arthritis, advances in the knowledge of the many disorders continue to produce improved drugs and therapies for the condition. Hence, the demand for medications to treat musculoskeletal problems will surge as the prevalence of arthritis rises in the region, boosting market expansion in North America.

The US market dominated the North America Musculoskeletal Disorders Drugs Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $28,248 Million by 2029. The Canada market is exhibiting a CAGR of 5% during (2023 - 2029). Additionally, The Mexico market would experience a CAGR of 4.7% during (2023 - 2029).

Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Drug Type, the market is segmented into Analgesics, DMARDs, Corticosteroids and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Eli Lilly And Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.

Scope of the Study

Market Segments covered in the Report:

By Distribution Channel

• Drug Stores & Retail Pharmacies
• Hospital Pharmacies
• Online Providers

By Route of Administration

• Parenteral
• Oral

By Drug Type

• Analgesics
• DMARDs
• Corticosteroids
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• AbbVie, Inc.
• Amgen, Inc.
• Eli Lilly And Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free